Small fragments of plastic were found in 9 out of 10 patients with prostate cancer, and in higher levels inside tumors than ...

K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with high unmet medical need, today announced data from its Phase ...

New research from NYU Langone Health detects microplastics in 9 out of 10 prostate cancer tumours, with levels 2.5× higher ...

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

When the scientists analyzed the tissue samples, they found microplastic particles in nine out of ten tumor samples. Even ...

Targeted cancer therapies are an expanding field of effective therapeutic approaches. While previous chemotherapy agents indiscriminately killed rapidly proliferating cells, newer “precision medicine” ...

Researchers describe the mechanisms of how alterations in the CDK12 gene drive prostate cancer development and report on a promising degrader that targets CDK12 and a related gene to destroy tumors.

A new study from Cold Spring Harbor Laboratory Professor Lloyd Trotman and colleagues, published in Science, shows that menadione significantly slows prostate cancer growth in mice and in ...

Telomir-1 has already been shown in multiple human cell lines to successfully elongate telomeres, raising this theoretical risk. However, this latest study demonstrates that Telomir-1 does not promote ...